Latest news

Adalvo, one of Europe’s leading B2B pharmaceutical companies, today announced the appointment of Anja Stapelfeld as Chief Human Resources Officer, effective immediately. The appointment reflects Adalvo’s continued investment in its...

Extending the company's dossier list in one of the most commercially relevant oral diabetes therapies in the global generics market.  Zug, Switzerland, 10 August 2026: Adalvo today announced the submission of...

Confirmed bioequivalence advances a complex haematology asset toward a global dossier and Day-1 launches across the US, EU and Rest of World.  Zug, Switzerland, 7 Aug 2026: Adalvo today announced...

An expanded co-development partnership, backed by shared investment, a resilient dual supply chain and cost leadership, positioning both companies at the forefront of one of the fastest-growing markets in medicine....

Milestone positions Adalvo as a global leader in one of the world's largest and fastest-growing markets for GLP-1 therapies, with Sandoz as commercial partner. Adalvo, one of Europe's leading B2B...

Parallel regulatory routes position a high-value rare disease asset for Day-1 launches across Europe.  Zug, Switzerland, 24th July 2026 — Adalvo today announced two regulatory milestones for its generic Tafamidis...

Results advance a high-value oncology asset towards regulatory submission and Day-1 launches across priority global markets, including the US.  Zug, Switzerland, 22nd July 2026 — Adalvo today announced positive results...

Switzerland, 20 July 2026 — Adalvo has entered into a partnership with humanitarian aid organization Direct Relief to expand access to essential medicines for underserved communities worldwide. The partnership marks...

As emergency relief efforts continue following the earthquake in Venezuela, Adalvo is supporting UNICEF’s work on the ground. At times like this, access to healthcare and essential support is critical....

Adalvo announces the first-to-market launch of generic Macitentan 10 mg film-coated tablets in Estonia, Latvia and Lithuania, in partnership with Norameda — the first generic version of the therapy available...

Adalvo and Amneal Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two Abbreviated New Drug Applications (ANDAs) filed at NCE-1 for generic tirzepatide...

Adalvo has completed pilot bioequivalence studies for generic Letermovir film-coated tablets. The programme will now advance into pivotal bioequivalence studies, ahead of filings in multiple markets.  As a high-barrier antiviral...

Adalvo is preparing filings for its generic linagliptin/metformin fixed-dose combination (FDC) tablet across multiple regions, including Europe via the DCP. The move advances the programme towards global market entry.  It...

Adalvo is submitting its dossier for generic dolutegravir film-coated tablets through the European DCP.  Dolutegravir — marketed as Tivicay (ViiV Healthcare) — is a cornerstone of WHO-recommended first-line HIV treatment...

Adalvo, the global B2B pharmaceutical company specialising in dossier development and out-licensing across 140+ markets, today announces the appointment of Rannveig Borg Sigurðardóttir as Chief Legal Officer. Based in Switzerland...

We are excited to announce we have received DCP approval across EU markets for our generic tacrolimus topical ointment (0.03% and 0.1% strengths), further expanding our dermatology portfolio.  Based on...

Adalvo has successfully completed the pivotal fed study for Avatrombopag 20 mg film-coated tablets. This milestone supports the progression towards regulatory submission and Day-1 launches across the US, EU and...

Adalvo is pleased to announce the signing of two new strategic distribution partnerships with Blanver, a prominent Brazilian pharmaceutical company, for two technically differentiated, value-add oncology products. These agreements further...

Adalvo and Cipla are pleased to announce the expansion of their strategic partnership with the launch of Vyfocis® capsules in South Africa. The launch represents a significant step in both...